256656-75-4

Upstream product

• 990-91-0 dibenzyl [[bis(benzyloxy)phosphoryl]oxy]phosphonate 
• 108549-23-1 Dibenzyl N,N-diisopropylphosphoramidite 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 948843-02-5 methyl 2-(4-((bis(benzyloxy)phosphoryl)oxy)phenyl)acetate 

Downstream Products

• 948843-03-6 2-(4-(bis(benzyloxy)phosphoryloxy)phenyl)acetic acid silver salt 
• 1401907-56-9 (4-phosphonooxyphenyl)acetic acid 4'-[2-[1-(2,6-dichlorophenyl)-1-methylethyl]-4-(1-hydroxy-1-methylethyl)imidazol-1-yl]-3,3'-difluoro-5-methanesulfonylbiphenyl-4-ylmethyl ester 
• 1401907-76-3 (4'-(2-(2-(2,6-dichlorophenyl)propan-2-yl)-4-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)-3,3'-difluoro-5-(methylsulfonyl)biphenyl-4-yl)methyl 2-(4-(bis(benzyloxy)phosphoryloxy)phenyl)acetate 

Relevant academic research and scientific papers

PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.

PRODRUGS OF LXR MODULATING IMIDAZOLE DERIVATIVES

Imidazole prodrugs, pharmaceutically acceptable salts, or isomers thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using

PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS

Compounds having the Formula (I), including pharmaceutically acceptable salts thereof, wherein at least one of X1, X2 or X3 is and any remaining X1, X2 or X3 is hydrogen, which are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, A1, A2 and m are as described herein.